Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice (Q37757656)

22 August 2017

1 reference

title

Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice (English)

1 reference

22 August 2017

0 references

0 references

0 references

7

1 reference

22 August 2017

Gerhard Walzl

5

0 references

Madhukar Pai

object named as

Madhukar Pai

2

0 references

Dick Menzies

3

object named as

Dick Menzies

1 reference

22 August 2017

Robert S Wallis

1

1 reference

22 August 2017

T Mark Doherty

4

1 reference

22 August 2017

Mark D Perkins

6

1 reference

22 August 2017

language of work or name

English

0 references

publication date

18 May 2010

1 reference

22 August 2017

1 reference

22 August 2017

375

1 reference

22 August 2017

1920-1937

1 reference

22 August 2017

9729

1 reference

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Biomarkers for tuberculosis disease activity, cure, and relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Induction of the antigen 85 complex of Mycobacterium tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Predicting the outcome of therapy for pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Sputum Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to antituberculosis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a High HIV prevalence setting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Low sensitivity of a urine LAM-ELISA in the diagnosis of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Clinical and radiological features in relation to urinary excretion of lipoarabinomannan in Ethiopian tuberculosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Detection of Mycobacterium tuberculosis antigens in urinary proteins of tuberculosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Combined Use of Serum and Urinary Antibody for Diagnosis of Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Identification and characterization of Mycobacterium tuberculosis antigens in urine of patients with active pulmonary tuberculosis: an innovative and alternative approach of antigen discovery of useful microbial molecules.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Identification of Mycobacterium tuberculosis ornithine carboamyltransferase in urine as a possible molecular marker of active pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

The scent of Mycobacterium tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Volatile biomarkers of pulmonary tuberculosis in the breath.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

A whole blood bactericidal assay for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Lack of activity of orally administered clofazimine against intracellular Mycobacterium tuberculosis in whole-blood culture

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Whole Blood Bactericidal Activity during Treatment of Pulmonary Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Changes in the kinetics of intracellular IFN-gamma production in TB patients during treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

In vivo and in vitro effects of antituberculosis treatment on mycobacterial interferon-gamma T cell response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Transitional changes in T-cell responses to Mycobacterium tuberculosis-specific antigens during treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

T-SPOT.TB responses during treatment of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Ex vivo cytokine mRNA levels correlate with changing clinical status of ethiopian TB patients and their contacts over time

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

In vivo and in vitro studies of a novel cytokine, interleukin 4delta2, in pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Differential expression of interleukin-4 (IL-4) and IL-4 delta 2 mRNA, but not transforming growth factor beta (TGF-beta), TGF-beta RII, Foxp3, gamma interferon, T-bet, or GATA-3 mRNA, in patients with fast and slow responses to antituberculosis tre

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Immune activation, allergic drug toxicity and mortality in HIV-positive tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Serum interleukin-2 and neopterin levels as useful markers for treatment of active pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Neopterin, beta 2-microglobulin, and acute phase proteins in HIV-1-seropositive and -seronegative Zambian patients with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Neopterin as an index of immune response in patients with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Procalcitonin and neopterin correlation with aetiology and severity of pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Elevation of procalcitonin level in patients with pulmonary tuberculosis and in medical staff with close patient contact

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Adalimumab treatment of life-threatening tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Serum C-reactive protein and detection of tuberculosis in persons co-infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Predicting deterioration of treated tuberculosis by corticosteroid reserve and C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Changes of plasma interleukin-1 receptor antagonist, interleukin-8 and other serologic markers during chemotherapy in patients with active pulmonary tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

The non-immune inflammatory response: serial changes in plasma iron, iron-binding capacity, lactoferrin, ferritin and C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Biomarkers for TB treatment response: challenges and future strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Elevated levels of circulating adhesion molecules in patients with active pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Expression of CDllc in blood monocytes as biomarker for favorable response to antituberculosis treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Screening for tuberculosis among 2381 household contacts of sputum-smear-positive cases in The Gambia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Relationship between whole-blood interferon-gamma responses and the risk of active tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Interferon gamma, interferon-gamma-induced-protein 10, and tuberculin responses of children at high risk of tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Is IP-10 a better biomarker for active and latent tuberculosis in children than IFNgamma?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

The 6-kilodalton early secreted antigenic target-responsive, asymptomatic contacts of tuberculosis patients express elevated levels of interleukin-4 and reduced levels of gamma interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

ESAT-6/CFP10 skin test predicts disease in M. tuberculosis-infected guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Bacillus Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

The effect of bacille Calmette-Guérin vaccine strain and route of administration on induced immune responses in vaccinated infants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Novel application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell frequency in field studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Evaluation of Human Antimycobacterial Immunity Using Recombinant Reporter Mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Novel human in vitro system for evaluating antimycobacterial vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Failure to control growth of mycobacteria in blood from children infected with human immunodeficiency virus and its relationship to T cell function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Reconstitution of antimycobacterial immune responses in HIV-infected children receiving HAART.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

A single dose of vitamin D enhances immunity to mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Strain specificity of antimycobacterial immunity in whole blood culture after cure of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

CD4(+) and CD8(+) T cells kill intracellular Mycobacterium tuberculosis by a perforin and Fas/Fas ligand-independent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Blood and urine samples as useful sources for the direct detection of tuberculosis by polymerase chain reaction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

PCR-based detection of the Mycobacterium tuberculosis complex in urine of HIV-infected and uninfected pulmonary and extrapulmonary tuberculosis patients in Burkina Faso.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Identification of HIV patients with active pulmonary tuberculosis using urine based polymerase chain reaction assay

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Development and validation of a protein-based signature for the detection of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Use of a T-cell interferon- release assay for the diagnosis of tuberculous pleurisy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Immunoreactivity of five antigens of Mycobacterium tuberculosis in patients attending a public health care facility in an area with high endemicity for TB.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Dynamic Antigen-specific T-Cell Responses after Point-Source Exposure toMycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Temporal dynamics of interferon gamma responses in children evaluated for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Serial testing of health care workers for tuberculosis using interferon-gamma assay

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

PPD induced in vitro interferon gamma production is not a reliable correlate of protection against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Dendritic cell stimulation by mycobacterial Hsp70 is mediated through CCR5.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Medicine. The NIH Roadmap

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Overview of biomarkers and surrogate endpoints in drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

The value, qualification, and regulatory use of surrogate end points in drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Tuberculosis control and elimination 2010–50: cure, care, and social development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Facing the crisis: improving the diagnosis of tuberculosis in the HIV era.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Partnering for better microbial diagnostics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

The global fight against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Working without a blindfold: the critical role of diagnostics in malaria control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Biomarkers for tuberculosis disease activity, cure, and relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Confronting the scientific obstacles to global control of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

How can immunology contribute to the control of tuberculosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Eliminating latent tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

The spectrum of latent tuberculosis: rethinking the biology and intervention strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

The prognosis of latent tuberculosis: can disease be predicted?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Spectrum of latent tuberculosis — existing tests cannot resolve the underlying phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

IFNgamma response to Mycobacterium tuberculosis, risk of infection and disease in household contacts of tuberculosis patients in Colombia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Tuberculosis drug resistance mutation database

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

New diagnostics for latent and active tuberculosis: state of the art and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Progress towards improved tuberculosis diagnostics for developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

New plan seeks to accelerate African diagnostic capacity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Novel and improved technologies for tuberculosis diagnosis: progress and challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Evidence-based tuberculosis diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Light-emitting diode technologies for TB diagnosis: what is on the market?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

New policies, new technologies: modelling the potential for improved smear microscopy services in Malawi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Comprehensive new resource for evidence-based TB diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

International standards for tuberculosis care

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Point-of-care diagnostics for global health

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Neglected tests for neglected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

New approaches and emerging technologies in the diagnosis of childhood tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Performance of purified antigens for serodiagnosis of pulmonary tuberculosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Rapid diagnosis of tuberculosis through the detection of mycobacterial DNA in urine by nucleic acid amplification methods

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Quality and reporting of diagnostic accuracy studies in TB, HIV and malaria: evaluation using QUADAS and STARD standards

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

TB diagnostic tests: how do we figure out their costs?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

GRADE: assessing the quality of evidence for diagnostic recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Grading quality of evidence and strength of recommendations for diagnostic tests and strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Reducing the global burden of tuberculosis: the contribution of improved diagnostics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

The persistence of tuberculosis in the age of DOTS: reassessing the effect of case detection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Averting epidemics of extensively drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Drivers of tuberculosis epidemics: the role of risk factors and social determinants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960359-5

7 January 2021

10.1016/S0140-6736(10)60359-5

Identifiers

DOI

1 reference

22 August 2017

1 reference